Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
about
Update on rational targeted therapy in AMLPolymeric micelles for multi-drug delivery in cancerImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysDaunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia ModelFuture prospects of therapeutic clinical trials in acute myeloid leukemia.Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Clinical Translation of Nanomedicine.Emerging therapies for acute myeloid leukemia.Acute myeloid leukemia: 2014 update on risk-stratification and management.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.Rational Combinations of Targeted Agents in AMLCollaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.Improving nucleoside analogs via lipid conjugation: Is fatter any better?Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.DNA Origami: Folded DNA-Nanodevices That Can Direct and Interpret Cell BehaviorPhotonanomedicine: a convergence of photodynamic therapy and nanotechnology.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.Novel drugs for older patients with acute myeloid leukemia.Nanomedicine: a pharma perspective.New treatment for acute myelogenous leukemia.Chemotherapy options for previously untreated acute myeloid leukemia.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Emerging therapeutic drugs for AML.Acute myeloid leukemia in the elderly: therapeutic options and choice.Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer.What are the latest advancements in acute myeloid leukemia therapy?The safety of treatment options for elderly people with acute myeloid leukemia.Emerging strategies for the treatment of older patients with acute myeloid leukemia.Acute Myeloid Leukemia in the Elderly Patient: New StrategiesTreatment of Elderly Patients With Acute Myeloid Leukemia.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low ToxicityPhase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
P2860
Q26766152-7E2A215A-AE9E-4707-97F7-89E4FD481106Q27025861-996F0399-7BBA-445E-8749-3D52501B959BQ28077848-BC41CCB2-C159-4713-87DD-F1B36C3B7679Q28833494-A65337DE-91FA-48EF-A788-B3455306DB7CQ30244168-A579AFB5-68FE-4FFF-8737-8B8188EA39CDQ30279055-EE468513-A3AF-4C75-9D2F-3B6DF777A3F9Q30355939-BCDFDF48-FC6D-4914-A5CD-06CD09E8D72EQ33576363-74BDAE1A-E125-4A17-B7A8-F8AB4C29EB4AQ34665691-DC1FACC1-DAE9-4B5F-9B8D-90B4E59BBD09Q34715598-E98DA358-28A4-4101-ADCA-ADE2C4E42F0FQ35581741-8A77B222-5C5A-4EE9-8CD9-B5BD32DE1B6FQ35750491-7CC8CC86-ECBA-4A7A-8DBA-55F3AACD45D2Q36053792-DDC8A6AB-1727-4BBD-A804-95545662BBA1Q36684345-25FAA487-D5F8-4B4A-8B8A-53CE9F2DA4CCQ36706248-7AB9FA44-D2C4-4084-A789-09054EECAEEEQ36709001-1B627948-DF21-46C2-964E-6BF639E5710DQ37095666-225E882A-5405-4E0F-BE40-48369C1018D5Q37115994-B116A8E5-69F9-4BF8-A55B-E23FF8D54FECQ37221579-E0A18697-E047-4C32-A2D6-7912FEDD48E4Q37624593-4BC208A4-44C7-45E9-9593-42125D73DF18Q37625632-41313CEE-7A8C-484D-9616-1A0B60B1E851Q38241761-19950F4F-85E3-4298-AEFC-B01D55E97DF8Q38246663-D1571F63-A6BC-4CF3-AA46-D452BABBA4B6Q38284045-38EFD12C-1776-4EC7-B1DB-2D97471E64A4Q38585930-B6A837BD-D38D-4D49-B260-CEBBF9891FC2Q38601723-825C7E0E-7F66-4B1E-89A7-9EFA45D7646EQ38644941-7928C7BC-A5F1-445C-AA0E-57647B856B55Q38664735-38982412-8966-4CC2-8377-14C1EC16D072Q38667491-3C8AF56C-23F0-4B40-AC20-3695BCF14FEEQ38675781-588B0397-766B-4CD5-B524-EEB91CF0E1B0Q38729106-C15E4E75-64D2-4CD6-A408-6CD05CCF0BAAQ38749830-406F5562-1D50-4BDA-8284-BF84646210C9Q38760822-7667BD4E-2805-47F5-A037-B4637F54E5E0Q38818726-2B14B559-CCBB-4934-82E8-953A404C30ABQ38835119-904936EE-B1A3-4851-A3CC-6365E7FBD690Q39112940-EC4FEE4E-8254-4D4A-A1CF-3296A053A357Q39175665-0E116C16-EE91-4DB0-9323-E1899B7CE31BQ40827250-0BFE14AD-0463-48A5-9ACD-803B76A7BDB6Q41132341-E2CAAAE6-5CC3-4033-A846-34E617C52CC0Q41240646-42BF6679-5E59-4A08-B9A4-B2DA994694F5
P2860
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Phase 2 trial of CPX-351, a fi ...... der adults with untreated AML.
@ast
Phase 2 trial of CPX-351, a fi ...... der adults with untreated AML.
@en
type
label
Phase 2 trial of CPX-351, a fi ...... der adults with untreated AML.
@ast
Phase 2 trial of CPX-351, a fi ...... der adults with untreated AML.
@en
prefLabel
Phase 2 trial of CPX-351, a fi ...... der adults with untreated AML.
@ast
Phase 2 trial of CPX-351, a fi ...... der adults with untreated AML.
@en
P2093
P2860
P1433
P1476
Phase 2 trial of CPX-351, a fi ...... der adults with untreated AML.
@en
P2093
Andrew M Yeager
Arthur C Louie
Donna E Hogge
Eric J Feldman
Jeffrey E Lancet
Jonathan E Kolitz
Lloyd E Damon
Maureen Cooper
Rami Komrokji
Scott R Solomon
P2860
P304
P356
10.1182/BLOOD-2013-12-540971
P407
P577
2014-03-31T00:00:00Z